A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above
1/2상
완료
NCT06361875
| 대상 질환 | Influenza Immunization, Healthy Volunteers |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | Sanofi Pasteur, a Sanofi Company |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 908 명 |
|---|
| 중재(약물) | Quadrivalent Influenza mRNA Vaccine MRT5421, Quadrivalent Influenza mRNA Vaccine MRT5424, Quadrivalent Influenza mRNA Vaccine MRT5429, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza High-Dose Vaccine |
|---|
| 시작일 | 2024년 4월 1일 |
|---|
| 완료일 | 2025년 6월 9일 |
|---|
| 결과 공개일 | 2026년 8월 4일 |
|---|
요약
The purpose of this study was to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of different formulations of Quadrivalent Influenza Vaccine (QIV) messenger ribonucleic acid (mRNA) (MRT5421, MRT5424, and MRT5429) compared to an active control (QIV- standard dose (SD), QIV- high dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) After Vaccine Administration
Within 30 minutes after vaccine administration on Day 1 · Participants
| QIV mRNA LNP 1: 30 mcg | 1 Participants |
|---|
| QIV mRNA LNP 1: 96 mcg | 1 Participants |
|---|
| QIV mRNA LNP 1: 132 mcg | 1 Participants |
|---|
| QIV mRNA LNP 1: 192 mcg | 0 Participants |
|---|
| QIV mRNA LNP 2: 96 mcg | 1 Participants |
|---|
| QIV mRNA LNP 2: 192 mcg | 0 Participants |
|---|
Number of Participants With Solicited Injection Site Reactions After Vaccine Administration
Within 7 days after vaccine administration on Day 1 · Participants
| QIV mRNA LNP 1: 30 mcg | 11 Participants |
|---|
| QIV mRNA LNP 1: 96 mcg | 71 Participants |
|---|
| QIV mRNA LNP 1: 132 mcg | 76 Participants |
|---|
| QIV mRNA LNP 1: 192 mcg | 79 Participants |
|---|
| QIV mRNA LNP 2: 96 mcg | 74 Participants |
|---|
| QIV mRNA LNP 2: 192 mcg | 17 Participants |
|---|
Number of Participants With Solicited Systemic Reactions After Vaccine Administration
Within 7 days after vaccine administration on Day 1 · Participants
| QIV mRNA LNP 1: 30 mcg | 15 Participants |
|---|
| QIV mRNA LNP 1: 96 mcg | 58 Participants |
|---|
| QIV mRNA LNP 1: 132 mcg | 71 Participants |
|---|
| QIV mRNA LNP 1: 192 mcg | 73 Participants |
|---|
| QIV mRNA LNP 2: 96 mcg | 60 Participants |
|---|
| QIV mRNA LNP 2: 192 mcg | 18 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.